ATR and renal cell carcinoma: Another ATR inhibitor, Ceralasertib, is being evaluated alone or in combination with olaparib or durvalumab in a phase II study enrolling patients with RCC and other solid tumors (ClinicalTrials.gov ID NCT03682289)